Senseonics (NYSE:SENS) announced today that the FDA granted approval to its next-generation continuous glucose monitor system.
Germantown, Maryland-based Senseonics designed the Eversense E3, which includes proprietary sacrificial boronic acid (SBA) technology, to extend longevity to six months (180 days), having previously offered the system with a 90-day wear time.
Get the full story at our sister site, Drug Delivery Business News.